Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | GLP1R | P43220 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25267995 | 1.00 | ALDH1A1 (0.35) | ALDH1A1NTRK1HPGDGLP1R | |
| SCHEMBL21175379 | 0.92 | ALDH1A1 (0.35) | ALDH1A1NTRK1 | |
| SCHEMBL21175291 | 0.91 | NTRK1 (0.36) | ALDH1A1NTRK1HPGD | |
| SCHEMBL20014817 | 0.90 | NTRK1 (0.34) | ALDH1A1NTRK1GLP1R | |
| SCHEMBL28952289 | 0.90 | NTRK1 (0.34) | ALDH1A1NTRK1GLP1R | |
| SCHEMBL31692362 | 0.85 | NTRK1 (0.35) | ALDH1A1NTRK1HPGD | |
| SCHEMBL38651834 | 0.85 | NTRK1 (0.34) | NTRK1 | |
| SCHEMBL30944794 | 0.83 | NTRK1 (0.31) | NTRK1 | |
| SCHEMBL31424290 | 0.82 | NTRK1 (0.31) | NTRK1 | |
| SCHEMBL22750903 | 0.82 | ALDH1A1 (0.33) | ALDH1A1NTRK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4097099-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4349840-A2 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-10 | — | — | EP | disclosed |
| EP-3517538-B1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-13 | — | — | EP | disclosed |
| US-11926643-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230382912-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-30 | — | — | US | disclosed |
| CN-117069743-A | GLP-1 receptor agonist | 北京盛诺基医药科技股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-11814381-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-14 | — | — | US | disclosed |
| US-20230174565-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-08 | — | — | US | disclosed |
| EP-4134367-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-02-15 | — | — | EP | disclosed |
| US-20210017176-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-01-21 | — | — | US | disclosed |
| US-10858356-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-12-08 | — | — | US | disclosed |
| EP-3517538-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | Chugai Seiyaku Kabushiki Kaisha (JP) | 2019-07-31 | — | — | EP | disclosed |
| US-20190225604-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225604-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | ALDH1A1 2311/4885NTRK1 1296/4885HPGD 1669/4885 |
| US-11926643-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | ALDH1A1 840/4885NTRK1 2648/4885HPGD 919/4885 |
| US-20230382912-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | ALDH1A1 2311/4885NTRK1 1296/4885HPGD 1669/4885 |
| US-20210017176-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | ALDH1A1 2103/4885NTRK1 1086/4885HPGD 3191/4885 |
| US-11814381-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | ALDH1A1 2099/4885NTRK1 1098/4885HPGD 2948/4885 |
| US-10858356-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | ALDH1A1 2311/4885NTRK1 1296/4885HPGD 1669/4885 |
| US-20230174565-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | ALDH1A1 840/4885NTRK1 2648/4885HPGD 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.